Moderna jumps premarket after Phase 3 trial, Target slides By Investing.com

▪

Moderna shares jumped as much as 96% in premarket trading Wednesday after the drugmaker and Merck announced positive Phase 3 results for their personalized mRNA melanoma therapy, intismeran autogene (mRNA-4157/V940), combined with Merck's Keytruda . The INTerpath-001 trial met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected stage IIB-IV melanoma, marking the first positive Phase 3 results for an individualized neoantigen therapy . Meanwhile, Target shares fell 4% despite beating expectations with a 3.8% comparable sales increase and $4.11 adjusted EPS, as investors focused on tariff-related benefits—a nearly $1 billion quarterly boost—and the company's underlying profit outlook excluding those gains . U.S. stock futures traded mixed amid a deepening global bond selloff pushing the 30-year Treasury yield to 5.33%, a 19-year high, and oil prices above $90 a barrel on Middle East tensions .

Reviewed by editorial team.

Media Bias

Articles Published:: 24
Right Leaning:: 0
Left Leaning:: 0
Neutral:: 24

Explain Framing

Left: Emphasizes healthcare access, affordability, and equitable cancer treatment availability concerns. Center: Focuses on clinical trial data, market reactions, and balanced corporate performance reporting. Right: Highlights market-driven innovation, shareholder value, and deregulation enabling medical breakthroughs.